查看所有供应商和价格请点击：

865466-24-6

865466-24-6结构式

中文名	(2S)-2-((4-(((2,7-二甲基-4-氧代-1,4-二氢喹唑啉-6-基)甲基)(丙-2-炔基)氨基)-2-氟苯甲酰)氨基)-4-(1H-四唑-5-基)丁酸
英文名	(1R,2S,5S)-3-[(2S)-2-[[1-(tert-butylsulfonylmethyl)cyclohexyl]carbamoylamino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
英文别名	(1R,2S,5S)-3-((S)-2-(3-(1-(tert-butylsulfonylmethyl)cyclohexyl)ureido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (1R,2S,5S)-N-[(3S)-1-(Cyclopropylamino)-1,2-dioxo-3-heptanyl]-6,6-dimethyl-3-{3-methyl-N-[(1-{[(2-methyl-2-propanyl)sulfonyl]methyl}cyclohexyl)carbamoyl]-L-valyl}-3-azabicyclo[3.1.0]hexane-2-carboxamide CS-0445 Narlaprevir (USAN/INN) Narlaprevir (1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]pentyl]-3-[2(S)-[[[[1-[[(1,1-dimethylethyl)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(1S)-1-[2-(cyclopropylamino)-1,2-dioxoethyl]pentyl]-3-[(2S)-2-[[[[1-[[(1,1-dimethylethyl)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-, (1R,2S,5S)-

描述	Narlaprevir是口服生物相容性的NS3蛋白酶抑制剂,Ki为6 nM,EC90为40 nM。
相关类别	信号通路 >> 代谢酶/蛋白酶 >> HCV蛋白酶信号通路 >> 抗感染 >> HCV 研究领域 >> 感染
参考文献	[1]. Ashok Arasappan, et al. Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor. ACS Med. Chem. Lett., 2010, 1 (2), pp 64–69 [2]. Tong X, Arasappan A, Bennett F, Chase R, Feld B, Guo Z, Hart A, Madison V, Malcolm B, Pichardo J, Prongay A, Ralston R, Skelton A, Xia E, Zhang R, Njoroge FG.Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.Antimicrob Agents Chemother. 2010 Jun;54(6):2365-70. Epub 2010 Mar 22. [3]. Zhu J, Li Y, Yu H, Zhang L, Mao X, Hou T.Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses.Comb Chem High Throughput Screen. 2012 Jul;15(6):439-50. [4]. de Bruijne J, Bergmann JF, Reesink HW, Weegink CJ, Molenkamp R, Schinkel J, Tong X, Li J, Treitel MA, Hughes EA, van Lier JJ, van Vliet AA, Janssen HL, de Knegt RJ.Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.Hepatology. 2010 Nov;52(5):1590-9. [5]. Tomillero A, Moral MA.Gateways to clinical trials.Methods Find Exp Clin Pharmacol. 2010 Nov;32(9):675-703.